Analgesics are expected to register double-digit value growth in 2020, though not as high as value growth over the review period. However, a lot of value growth over the review period has been driven by inflationary pressure and but several product areas are expected to see an increase in volume sales, as result of the COVID-19 in 2020, with adult acetaminophen expected to record the highest value growth.
GSK Consumer Healthcare remained the leading player in analgesics in 2020. The company offers three of the four leading brands: Panadol, Cataflam and Voltaren.
All product areas of OTC analgesics are expected to register positive growth in Egypt during 2020. However, during the review period ibuprofen has struggled to sustain consistent growth as consumers have shifted towards acetaminophen, which represents better value for money than ibuprofen.
Though COVID-19, could never be described as a good news story, analgesics, and in particular acetaminophen, have benefitted from being cited as a treatment to alleviate the symptoms of COVID-19, Due to stockpiling as a result of COVID-19 in 2020, value sales growth will be slightly lower in 2021. However, later in the forecast period and once the threat of COVID-19 subsides, analgesics will return to pre COVID-19 levels in terms of value growth.
Analgesics is set to continue registering consistently strong positive sales growth throughout the forecast period. One the main driver of value sales will be Egypt’s growing population.
Sales of diclofenac are expected to continue rising strongly during the forecast period. The top three brands in descending order are Cataflam, (GSK) Catafast (Novartis) and Voltaren (GSK) and in 2020, its value growth is expected to be just behind adult acetaminophen.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Analgesics industry in Egypt with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Egypt, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Analgesics research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page